1. Avoid taking live vaccines during
baricitinib treatment as it may affect the effectiveness of the vaccines.
2.Patients should be advised to check their lipid levels after 12 weeks of baricitinib treatment as there have been reports of abnormal levels of liver enzymes and lipid parameters such as total cholesterol and low-density lipoproteins (LDL) during baricitinib treatment.
3. Decreased levels of neutrophils, hemoglobin, and lymphocytes can occur during baricitinib treatment, and dose modifications or adjustments are recommended in such cases. In case of abnormally low levels, baricitinib treatment should be immediately stopped and the patient should be treated for blood disorders.
1.Stomach pain or related symptoms that occur during baricitinib treatment should be evaluated immediately to detect the presence of any gastrointestinal perforation and to get treated early.
2.Patients with a strong history or at an increased risk of acquiring skin cancer should perform periodic skin examination during baricitinib treatment to detect and treat cancers such as non-melanoma skin cancer(NMSC).
3.Screening for viral hepatitis should be done before starting treatment with baricitinib as the drug may cause viral reactivation.
4.Treatment should be stopped immediately if a patient develops herpes zoster during the treatment with baricitinib.
5. Patients should be examined for the presence of active or latent tuberculosis (TB) and should be treated first with antimycobacterial therapy before initiating baricitinib therapy if the patient tests positive for TB.
6. Patients should be monitored for the presence of any symptoms or signs of tuberculosis during baricitinib therapy as the infection can develop even in patients who tested negative for TB before starting the therapy.
